La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

CVS Health Gestione

Gestione criteri di controllo 3/4

CVS Health's Il CEO è Karen Lynch, nominato in Feb2021, e ha un mandato di 3.5 anni. la retribuzione annua totale è $ 21.62M, composta da 6.9% di stipendio e 93.1% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.04% delle azioni della società, per un valore di CLP 27.49B. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.4 anni e 6.5 anni.

Informazioni chiave

Karen Lynch

Amministratore delegato

US$21.6m

Compenso totale

Percentuale dello stipendio del CEO	6.9%
Mandato del CEO	3.7yrs
Proprietà del CEO	0.04%
Durata media del management	2.6yrs
Durata media del Consiglio di amministrazione	6.7yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Karen Lynch rispetto agli utili di CVS Health?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	US$7b
Mar 31 2024	n/a	n/a	US$7b
Dec 31 2023	US$22m	US$2m	US$8b
Sep 30 2023	n/a	n/a	US$9b
Jun 30 2023	n/a	n/a	US$3b
Mar 31 2023	n/a	n/a	US$4b
Dec 31 2022	US$21m	US$1m	US$4b
Sep 30 2022	n/a	n/a	US$3b
Jun 30 2022	n/a	n/a	US$8b
Mar 31 2022	n/a	n/a	US$8b
Dec 31 2021	US$20m	US$1m	US$8b
Sep 30 2021	n/a	n/a	US$8b
Jun 30 2021	n/a	n/a	US$7b
Mar 31 2021	n/a	n/a	US$7b
Dec 31 2020	US$11m	US$1m	US$7b

Compensazione vs Mercato: La retribuzione totale di Karen ($USD 21.62M ) è superiore alla media delle aziende di dimensioni simili nel mercato CL ($USD 6.09M ).

Compensazione vs guadagni: La retribuzione di Karen è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Karen Lynch (61 yo)

3.7yrs

Mandato

US$21,615,034

Compensazione

Ms. Karen Sue Lynch serves as Chief Executive Officer, President and Director at CVS Health Corporation since February 01, 2021. She has extensive experience in the health care industry. She was Executive...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Karen Lynch	President	3.7yrs	US$21.62m	0.040% CLP 29.1b
Thomas Cowhey	Executive VP & CFO	less than a year	US$4.58m	0.0028% CLP 2.0b
Tilak Mandadi	Executive VP of Ventures and Chief Digital	2.3yrs	US$8.88m	0.0032% CLP 2.3b
Samrat Khichi	Executive VP	1.7yrs	US$11.89m	0.00078% CLP 563.8m
Prem Shah	Executive VP	2.9yrs	US$8.58m	0.0037% CLP 2.7b
Vijay Patel	Senior Director of Business Development & CVS Health and Partner & Co-Founder	no data	Nessun dato	Nessun dato
James Clark	Senior VP	5.9yrs	Nessun dato	0.00067% CLP 484.3m
David Falkowski	Executive VP & Chief Compliance Officer	no data	Nessun dato	Nessun dato
Heidi Capozzi	Executive VP & Chief People Officer	less than a year	Nessun dato	Nessun dato
J. Joyner	Executive Vice President & President of CVS Caremark	1.8yrs	Nessun dato	0.0032% CLP 2.3b
Michelle Peluso	Executive VP and Chief Customer & Experience Officer	3.8yrs	Nessun dato	0.0099% CLP 7.1b
Joneigh Khaldun	VP & Chief Health Equity Officer	3yrs	Nessun dato	Nessun dato

2.6yrs

Durata media

57yo

Età media

Gestione esperta: Il team dirigenziale di CVSCL è considerato esperto (durata media dell'incarico 2.4 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Karen Lynch	President	3.7yrs	US$21.62m	0.040% CLP 29.1b
J. Kirby	Independent Director	less than a year	US$195.42k	0.00045% CLP 325.3m
Roger Farah	Independent Chairman	5.9yrs	US$576.50k	0.00033% CLP 238.5m
Mary Schapiro	Independent Director	7.4yrs	US$301.50k	0.00094% CLP 679.4m
Nancy-Ann DeParle	Independent Director	11.1yrs	US$321.50k	0.0025% CLP 1.8b
Anne Finucane	Independent Director	13.8yrs	US$321.50k	0.0026% CLP 1.9b
C. Brown	Independent Director	17.6yrs	US$321.50k	0.0097% CLP 7.0b
Jean-Pierre Millon	Independent Director	17.6yrs	US$321.50k	0.0088% CLP 6.3b
Alecia DeCoudreaux	Independent Director	9.6yrs	US$301.50k	0.00024% CLP 173.5m
Fernando Aguirre	Independent Director	5.9yrs	US$318.17k	0.0028% CLP 2.0b
Jeffrey Balser	Independent Director	2.1yrs	US$301.50k	0.00058% CLP 419.2m
Michael Mahoney	Independent Director	less than a year	US$167.50k	0.0011% CLP 780.6m

6.7yrs

Durata media

67.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di CVSCL sono considerati esperti (durata media dell'incarico 6.5 anni).

CVS Health Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

CVS Health Announces CEO Changes

CVS Health Corporation Appoints Heidi Capozzi as Executive Vice President, Chief People Officer, Effective September 9, 2024

Insider recently bought CL$478m worth of stock

CVS Health Corporation, Annual General Meeting, May 16, 2024

Executive VP recently sold CL$2.2b worth of stock

CVS Health Announces Executive Changes

Recent updates

CVS Health Announces CEO Changes

CVS Health Reportedly Considers Sale of Its Insurance Business

Upcoming dividend of US$0.67 per share

Second quarter dividend of US$0.67 announced

CVS Health Announces Quarterly Dividend, Payable on November 1, 2024

Adherence Files Lawsuit Against CVS Health and Asembia for Alleged Unauthorized Use of Its Trademarked and Copyrighted Intellectual Property

CVS Health Announces Updated Flu and COVID-19 Vaccinations Now Available at CVS Pharmacy® and MinuteClinic®

CVS Health Corporation Appoints Heidi Capozzi as Executive Vice President, Chief People Officer, Effective September 9, 2024

Second quarter 2024 earnings released: EPS: US$1.41 (vs US$1.48 in 2Q 2023)

CVS Health Corporation Revises Earnings Guidance for the Full Year 2024

CVS Health Corporation Launches First-Of-Its-Kind Initiative to Support Patients Most Vulnerable to Health Impacts of Extreme Weather Events

First quarter dividend of US$0.67 announced

CVS Health Announces Quarterly Dividend, Payable on August 1, 2024

The Law Firms of Kessler Topaz Meltzer & Check, LLP and Carella, Byrne, Cecchi, Brody & Agnello, P.C. Files a Class Action Lawsuit Against CVS Health Corporation and Related Entities for Preventing SilverScript Members from Accessing Certain Generic Medications

Insider recently bought CL$478m worth of stock

First quarter 2024 earnings released: EPS: US$0.88 (vs US$1.67 in 1Q 2023)

CVS Health Corporation Revises Earnings Guidance for the Full Year 2024

Upcoming dividend of US$0.67 per share

CVS Health Corporation, Annual General Meeting, May 16, 2024

CVS Health Corporation to Report Q1, 2024 Results on May 01, 2024

Fourth quarter dividend of US$0.67 announced

Cvs Health Approves Quarterly Dividend on the Common Stock, Payable on May 1, 2024

Wisner Baum Files Multiple Class Actions Alleging Several Companies Sold Benzoyl Peroxide Acne Products Without Warning Consumers That They Contain Unsafe Levels of Benzene, a Potent Human Carcinogen

Executive VP recently sold CL$2.2b worth of stock

Full year 2023 earnings released: EPS: US$6.49 (vs US$3.16 in FY 2022)

Upcoming dividend of US$0.67 per share at 3.1% yield

CVS Health Corporation Provides Earnings Guidance for the Year 2023

CVS Health Announces Executive Changes

Robbins Geller Rudman & Dowd LLP and Aqualaw PLC Reaches Settlements in Class Action with Costco Wholesale Corporation, CVS Health Corporation, The Procter & Gamble Company, Target Corporation, Walgreen Co. and Walmart Inc

CVS Health Approves Quarterly Dividend, Payable on February 1, 2024

Independent Director recently bought CL$124m worth of stock

CVS Health Names Mark Santos as President, Aetna Medicaid

Independent Director recently bought CL$124m worth of stock

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media